AR054625A1 - Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos. - Google Patents
Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos.Info
- Publication number
- AR054625A1 AR054625A1 ARP060102713A ARP060102713A AR054625A1 AR 054625 A1 AR054625 A1 AR 054625A1 AR P060102713 A ARP060102713 A AR P060102713A AR P060102713 A ARP060102713 A AR P060102713A AR 054625 A1 AR054625 A1 AR 054625A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- cycloalkyl
- alkynyl
- alkenyl
- Prior art date
Links
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004599 antimicrobial Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 19
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- -1 methylenedioxy Chemical group 0.000 abstract 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 10
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 7
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 2
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000005605 benzo group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002757 morpholinyl group Chemical group 0.000 abstract 2
- 125000004193 piperazinyl group Chemical group 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 abstract 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 abstract 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 abstract 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 abstract 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 abstract 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- WCZBUQIZTSIQFE-UHFFFAOYSA-N furan;thiophene Chemical compound C=1C=COC=1.C=1C=CSC=1 WCZBUQIZTSIQFE-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 abstract 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
- YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Los compuestos de oxazolidinona de formula (1) son activos contra patogenos humanos y veterinarios Gram-positivos y algunos Gram-negativos con una débil actividad inhibidora de la monoaminooxidasa (MAO). Son utiles para el tratamiento de infecciones bacterianas. Reivindicacion 1: Un compuesto caracterizado porque comprende oxazoladinona de formula (1), en la que R1, R2, R3 y R4 se seleccionan independientemente de -H y halogeno; A se selecciona del grupo (2); R5 y R6 se seleccionan de forma independiente del grupo consistente en -H, -F, -Cl, -Br, -OH, -NO2, -CN, -CF3, -COR8, -CSR8, -SO2R8, -OCOR8, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6, -N-R21R22 y T; o R5 y R8 tomados conjuntamente forman un resto benzo condensado, pirido, furo, tieno, oxazolo, isoxazolo, tiazolo, isotiazolo, pirrolo, pirazolo o imidazo, pudiendo estar a su vez dichos restos condensados sustituidos con uno, dos o tres de los sustituyentes seleccionados del grupo consistente en -F, -CI, -Br, -OH, -NO2, -CN, -CF3, -COR8, -CSR8, -SO2R8, -OCOR8, alquilo C1-6, haloalquilo C1-6, cicloalquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6 y -N- R21R22, o un anillo condensado seleccionado de ciclopento, ciclohexo, ciclohepto, metilendioxi y etilendioxi, pudiendo estar a su vez dicho anillo condensado sustituido con uno, dos o tres de los sustituyentes seleccionados del grupo consistente en alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6 y alquinilo C2-6; R7 se selecciona del grupo consistente en -H, alquilo C1-6.opcionalmente sustituido, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, -N-R21R22 y T; o R7 y R5 o R6 tomados conjuntamente forman cuando es posible un anillo de 2 a 6 átomos de carbono y qué contiene de 1 a 3 grupos seleccionados de O, N, S, SO y SO2, que a su vez puede estar sustituido con uno, dos o tres de los sustituyentes seleccionados del grupo consistente en alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6 y alquinilo C2-6; R8 se selecciona del grupo consistente en -H, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6, hidroxialquilo C1-6, -N-R21R22 y T; R9 y R10 se seleccionan de forma independiente del grupo consistente en -H, -CN, -NO2, -COR11, -SO2R11, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1- 6alquilo C1-6, -N-R21R22 y T; R11 se selecciona del grupo consistente en -H, -OH, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6alquilo C1-6 y T; R12 y R13 se seleccionan de forma independiente del grupo consistente en -H, -OH, -CHR14R15, -CN, -COR14, -CSR14, -COOR14, -CSOR14, -CONR14R15, -CSNR14R15, -CON(R16)N(R14)R15, -SO2R14, -SO2OR14, -SO2NR14R15, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1- 6alquilo C1-6 y T; R14 y R15 se seleccionan de forma independiente del grupo consistente en -H, -OH, -COR16, -CSR16, -SO2R16, -NR17R18, alquilo C1-6 opcionalmente sustituido, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, fenilo, o el grupo (3); R16 es -H, -OH, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6, hidroxialquilo C1-6 y T; R17 y R18 se seleccionan de forma independiente del grupo consistente en -H, -OH, -F, -CI, - Br, -NO2, -CN, -NR19R20, -COR19, -CONR19R20, -SO2R19, -SO2NR19R20, alquilo C1-6 opcionalmente sustituido, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6 y T; o R17 y R18 tomados conjuntamente forman un resto benzo condensado, que a su vez puede estar sustituido con uno, dos o tres de los sustituyentes seleccionados del grupo consistente en -F, -CI, -Br, -OH, -NO2, -CN, -CF3, -COR8, -CSR8, -SO2R8, -OCOR8, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxi C1-6alquilo C1-6 y -NR21R22, o un anillo condensado seleccionado de ciclopento, ciclohexo, ciclohepto, metilendioxi y etilendioxi, pudiendo estar dicho anillo condensado a su vez sustituido con uno, dos o tres de los sustituyentes seleccionados del grupo consistente en alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6 y alquinilo C2-6; R19 y R20 se seleccionan de forma independiente del grupo consistente en -H, -OH, alquilo C1-6 opcionalmente sustituido, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6 y T; R21 y R22 se seleccionan independientemente de -H, alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6 y T, dichos grupos -N-R21R22 pueden representar un anillo heterocíclico seleccionado del grupo consistente en pirrolidinilo, piperidinilo, piperazinilo opcionalmente sustituido en N con alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6 o alquinilo C2-6, morfolinilo, tiomorfolinilo, tiomorfolinil S-oxido y tiomorfolinil S-dioxido; T representa un grupo fenilo o heteroarilo, cada uno de los cuales opcionalmente sustituido, seleccionándose dicho heteroarilo del grupo consistente en piridina, piridinazina, pirimidina, pirazina, furano tiofeno, oxazol, tiazol, imidazol, pirazol, isoxazol, isotiazol, 1,2,5-tiadiazol, furazano, 1,2,4-oxadiazol, 1,2,4-tiadiazol, 1,2,3-oxadiazol, 1,2,3- tiadiazol, tetrazol, 1,2,3,4-oxatriazol y 1,2,3,4-tiatriazol, pudiendo ser los sustituyentes opcionalmente presentes en el grupo fenilo opcionalmente sustituido o heteroarilo opcionalmente sustituido uno, dos o tres de los sustituyentes seleccionados del grupo consistente en -F, -CI, -Br, -OH, -NH2, -NO2, -CN, -CF3, -COR8, -CSR8, -SO2R8, -OCOR8, alquilo C1-6, haloalquilo C1-6, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6, alcoxiC1-6alquiIoC1-6, NH-alquilo C1-6, NH-cicloalquilo C3-6, -N-dialquilo C1-6, -N-(alquil C1-6)(cicloalquilo C3-6), metilendioxi, etilendioxi y un anillo heterocíclico seleccionado del grupo consistente en pirrolidinilo, piperidinilo, piperazínilo opcionalmente sustituido en N con alquilo C1-6, cicloalquilo C3-6, alquenilo C2-6 o alquinilo C2-6, morfolinilo, tiomorfolinilo, tiomorfolinil S-oxido y tiomorfolinil S-dioxido; X se selecciona entre O, S, NR9 y CR9R10; e Y se selecciona entre O, S, SO, SO2, NO, NR12 y CR12R13; y en la que los sustituyentes opcionales del grupo alquilo C1-6 pueden ser uno, dos o tres de los seleccionados del grupo consistente en -F, -CI, -NO2, -OR21, -COR21, -N-R21R22, oxo, cicloalquilo C3-6, alquenilo C2-6, alquinilo C2-6, -CN, T, -COO-R21, -OCOR21, - CON-R21R22, -N(R21)-CO-R22, -OCON-R21R22, y -N(R21)-COO-R22; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105714A EP1745784A1 (en) | 2005-06-27 | 2005-06-27 | Oxazolidinone derivatives and use thereof as antibiotics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054625A1 true AR054625A1 (es) | 2007-07-04 |
Family
ID=34982564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102713A AR054625A1 (es) | 2005-06-27 | 2006-06-23 | Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7759351B2 (es) |
| EP (2) | EP1745784A1 (es) |
| JP (1) | JP2008543963A (es) |
| KR (1) | KR20080020696A (es) |
| CN (1) | CN101248067A (es) |
| AR (1) | AR054625A1 (es) |
| AT (1) | ATE442366T1 (es) |
| AU (1) | AU2006263880A1 (es) |
| BR (1) | BRPI0612559A2 (es) |
| CA (1) | CA2612969A1 (es) |
| CY (1) | CY1109544T1 (es) |
| DE (1) | DE602006009112D1 (es) |
| DK (1) | DK1902050T3 (es) |
| ES (1) | ES2333469T3 (es) |
| MX (1) | MX2007016329A (es) |
| NO (1) | NO20080536L (es) |
| PL (1) | PL1902050T3 (es) |
| PT (1) | PT1902050E (es) |
| RU (1) | RU2417223C2 (es) |
| SI (1) | SI1902050T1 (es) |
| TW (1) | TWI324603B (es) |
| WO (1) | WO2007000432A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8466151B2 (en) | 2007-12-26 | 2013-06-18 | Critical Outcome Technologies, Inc. | Compounds and method for treatment of cancer |
| CA2730890C (en) | 2008-07-17 | 2018-05-15 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| RU2522582C2 (ru) | 2008-11-20 | 2014-07-20 | Панацеа Биотек Лтд. | Новые противомикробные средства |
| RU2012102094A (ru) | 2009-06-26 | 2013-08-10 | Панацеа Биотек Лтд. | Новые азабициклогексаны |
| EP2552915B1 (en) | 2010-04-01 | 2017-07-19 | Critical Outcome Technologies Inc. | Compounds for the treatment of hiv |
| WO2015004306A1 (es) * | 2013-07-11 | 2015-01-15 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de oxazolidinona como ligandos de ppar |
| CN103420995B (zh) * | 2013-09-07 | 2015-07-01 | 吉首大学 | 噁唑烷酮-烷胺基-呋喃酮型化合物及其制法和用途 |
| CN104447730B (zh) * | 2014-12-05 | 2017-11-07 | 广东东阳光药业有限公司 | 噁唑烷酮类化合物及其在药物中的应用 |
| TWI614256B (zh) | 2017-05-26 | 2018-02-11 | 合成四氫異喹啉噁唑烷的方法 | |
| KR102152445B1 (ko) * | 2017-09-28 | 2020-09-04 | 주식회사 엘지화학 | 의약품 합성용 중간체 화합물의 제조 방법 |
| WO2021184339A1 (en) | 2020-03-20 | 2021-09-23 | Merck Sharp & Dohme Corp. | Oxazolidinone compound and methods of use thereof as an antibacterial agent |
| BR112022025918A2 (pt) | 2020-06-18 | 2023-03-14 | Akagera Medicines Inc | Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos |
| CN115466253B (zh) * | 2021-06-16 | 2024-08-20 | 沈阳药科大学 | 含二硫代氨基甲酸酯结构的噁唑烷酮类化合物及其制备方法 |
| CN113880821B (zh) * | 2021-10-29 | 2024-03-12 | 南京碳硅人工智能生物医药技术研究院有限公司 | 一类双光子荧光探针对癫痫脑内次氯酸特征成像的荧光探针设计及其合成方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9901979A3 (en) * | 1995-09-01 | 2000-03-28 | Upjohn Co | Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings and pharmaceutical compositions containing the same |
| WO2003048136A1 (en) * | 2001-11-29 | 2003-06-12 | Merck & Co., Inc. | Cyclopropyl hexane containing oxazolidinone antibiotics and derivatives thereof |
| IL164195A0 (en) * | 2002-03-29 | 2005-12-18 | Upjohn Co | Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections |
| CA2492194A1 (en) * | 2002-07-11 | 2004-01-22 | Wockhardt Limited | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoproteins sites |
| AU2003215861A1 (en) * | 2003-04-07 | 2004-11-01 | Ranbaxy Laboratories Limited | Oxazolidinone derivatives as antimicrobials |
-
2005
- 2005-06-27 EP EP05105714A patent/EP1745784A1/en not_active Withdrawn
-
2006
- 2006-06-23 AR ARP060102713A patent/AR054625A1/es not_active Application Discontinuation
- 2006-06-26 PT PT06763881T patent/PT1902050E/pt unknown
- 2006-06-26 DK DK06763881T patent/DK1902050T3/da active
- 2006-06-26 BR BRPI0612559-0A patent/BRPI0612559A2/pt not_active IP Right Cessation
- 2006-06-26 MX MX2007016329A patent/MX2007016329A/es active IP Right Grant
- 2006-06-26 EP EP06763881A patent/EP1902050B1/en not_active Not-in-force
- 2006-06-26 TW TW095122882A patent/TWI324603B/zh not_active IP Right Cessation
- 2006-06-26 WO PCT/EP2006/063541 patent/WO2007000432A1/en not_active Ceased
- 2006-06-26 RU RU2008102597/04A patent/RU2417223C2/ru not_active IP Right Cessation
- 2006-06-26 AU AU2006263880A patent/AU2006263880A1/en not_active Abandoned
- 2006-06-26 SI SI200630494T patent/SI1902050T1/sl unknown
- 2006-06-26 CN CNA2006800309697A patent/CN101248067A/zh active Pending
- 2006-06-26 US US11/922,848 patent/US7759351B2/en not_active Expired - Fee Related
- 2006-06-26 KR KR1020087001902A patent/KR20080020696A/ko not_active Withdrawn
- 2006-06-26 PL PL06763881T patent/PL1902050T3/pl unknown
- 2006-06-26 AT AT06763881T patent/ATE442366T1/de active
- 2006-06-26 JP JP2008518807A patent/JP2008543963A/ja not_active Abandoned
- 2006-06-26 DE DE602006009112T patent/DE602006009112D1/de active Active
- 2006-06-26 CA CA002612969A patent/CA2612969A1/en not_active Abandoned
- 2006-06-26 ES ES06763881T patent/ES2333469T3/es active Active
-
2008
- 2008-01-28 NO NO20080536A patent/NO20080536L/no not_active Application Discontinuation
-
2009
- 2009-12-04 CY CY20091101273T patent/CY1109544T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200740800A (en) | 2007-11-01 |
| CN101248067A (zh) | 2008-08-20 |
| PT1902050E (pt) | 2009-11-27 |
| JP2008543963A (ja) | 2008-12-04 |
| PL1902050T3 (pl) | 2010-03-31 |
| MX2007016329A (es) | 2008-03-10 |
| EP1902050A1 (en) | 2008-03-26 |
| NO20080536L (no) | 2008-03-14 |
| KR20080020696A (ko) | 2008-03-05 |
| US20090062266A1 (en) | 2009-03-05 |
| RU2008102597A (ru) | 2009-08-10 |
| BRPI0612559A2 (pt) | 2010-11-23 |
| RU2417223C2 (ru) | 2011-04-27 |
| CA2612969A1 (en) | 2007-01-04 |
| AU2006263880A1 (en) | 2007-01-04 |
| EP1902050B1 (en) | 2009-09-09 |
| TWI324603B (en) | 2010-05-11 |
| DE602006009112D1 (de) | 2009-10-22 |
| DK1902050T3 (da) | 2010-01-04 |
| US7759351B2 (en) | 2010-07-20 |
| ATE442366T1 (de) | 2009-09-15 |
| EP1745784A1 (en) | 2007-01-24 |
| WO2007000432A1 (en) | 2007-01-04 |
| CY1109544T1 (el) | 2014-08-13 |
| SI1902050T1 (sl) | 2010-01-29 |
| HK1116482A1 (en) | 2008-12-24 |
| ES2333469T3 (es) | 2010-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054625A1 (es) | Compuestos de oxazolidinona,procedimiento para prepararlos,composiciones farmaceuticas que los contienen,y uso como agentes antimicrobianos. | |
| PE20030200A1 (es) | Bencimidazol como inhibidores de las map quinasas | |
| AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| AR073688A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
| AR046222A1 (es) | Composiciones farmaceuticas de liberacion sostenida que incluyen aplindore y sus derivados | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20041016A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| AR069412A1 (es) | Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras. | |
| PE20121440A1 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| AR040477A1 (es) | Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos | |
| PE20110924A1 (es) | Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 | |
| PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20051141A1 (es) | Inhibidores de la polimerasa viral | |
| PE20091492A1 (es) | Compuestos y composiciones como inhibidores de c-kit y de la cinasa pdgfr | |
| AR043367A2 (es) | Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion. | |
| PE20120764A1 (es) | Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |